Valneva Kickstarts Phase 3 Trial Of Chikungunya Vaccine Candidate In Adolescents


Valneva SE VALN has initiated a Phase 3 trial in adolescents for its single-shot chikungunya vaccine candidate, VLA1553.

  • The collaboration falls within the framework of the agreement signed between Coalition for Epidemic Preparedness Innovations and Valneva in July 2019, which provides funding of up to $23.4 million with support from the European Union's Horizon 2020 program.
  • It is also expected to support the vaccine's licensure in Brazil, the first potential approval for use in endemic populations.
  • Related: Valneva Posts Positive Lot-to-Lot Consistency Data For Its Single-Dose Chikungunya Vaccine.
  • The Phase 3 trial, dubbed VLA1553-321, will enroll 750 adolescents aged 12 to 17 years.
  • The trial's primary objective is to evaluate safety and immunogenicity following a single vaccination with VLA1553. 
  • Participants will be evaluated after 28 days and followed up to twelve months. 
  • The study will also provide safety and immunogenicity data in participants previously exposed to chikungunya.
  • In August 2021, Valneva reported topline results for the pivotal Phase 3 trial VLA1553-301 in adults aged 18 years and above. 
  • VLA1553-301 will continue towards the final analysis, including the 6-month safety data. The Company expects to report final trial results in early 2022.
  • The global market for vaccines against chikungunya is estimated to exceed $500 million annually by 2032.
  • Price Action: VALN shares closed at $34.07 on Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsChikungunyaPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!